Companion diagnostics refer to tests that help identify those patients who are most suitable for treatment with targeted therapies
Thermo Fisher Scientific and pharmaceutical companies, GlaxoSmithKline (GSK) and Pfizer have entered into an agreement to develop a universal next-generation sequencing (NGS) oncology test for solid tumors that will serve as a companion diagnostic for multiple drug programs.
The test will be developed using Thermo Fisher Scientific's Ion Personal Genome Machine (PGM) Dx Platform, Ion AmpliSeq technology, and content from the Oncomine Cancer Research Panel.
Companion diagnostics refer to tests that help identify those patients who are most suitable for treatment with targeted therapies.
Using the Ion PGM Sequencing Platform combined with Ion AmpliSeq technology, hundreds of genes can be simultaneously analyzed from tumor samples via next-generation sequencing, with high reproducibility and rapid turnaround time.
"To realize the promise of personalized medicine in oncology, cancer patients increasingly require multiple, complex genetic tests. Together with Pfizer, GSK, and potentially other pharmaceutical companies, we seek to change the paradigm and develop a single next-generation sequencing test that can provide a comprehensive analysis of multiple, relevant genetic markers," said Mr Dan Rhodes, head of Oncology for lifescience solutions at Thermo Fisher Scientific. He added, "This approach will help ensure that cancer patients have an opportunity to potentially benefit from a targeted therapy associated with their tumor's genetic profile."